All Companies

REGN

Regeneron Pharmaceuticals Inc

Pharmaceutical Preparations

$789.45updated Sep 18, 2026

Congressional trading profile for Regeneron Pharmaceuticals Inc (REGN), covering 14 disclosed transactions by 9 lawmakers.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Total Trades

14

Politicians Trading

9

Last Traded

Jul 7, 2026

Price history

Congressional Trades

PoliticianNotifiedTradedTypeAmountChange
Ro KhannaDAug 7, 2026Jul 7, 2026Buy$1,001 - $15,000+16.74%
Alan ArmstrongRJul 21, 2026Mar 27, 2026Buy$1,001 - $15,000+7.01%
Julia LetlowRMar 12, 2026Feb 12, 2026Buy$1,001 - $15,000+0.74%
Gilbert Ray Cisneros, Jr.DDec 15, 2025Nov 18, 2025Buy$1,001 - $15,000+8.84%
Robert BresnahanRJun 9, 2025May 15, 2025Buy$1,001 - $15,000+34.95%
Byron DonaldsRMay 24, 2025Apr 10, 2025Sell$1,001 - $15,000+44.48%
Byron DonaldsRMay 24, 2025Apr 10, 2025Sell$1,001 - $15,000+44.48%
Julie JohnsonDMay 14, 2025Apr 1, 2025Sell$1,001 - $15,000+27.95%
Robert BresnahanRMay 8, 2025Apr 8, 2025Sell$1,001 - $15,000+41.78%
Jefferson ShreveRMay 8, 2025Apr 7, 2025Sell$15,001 - $50,000+37.83%
Robert BresnahanRMar 27, 2025Feb 25, 2025Sell$1,001 - $15,000+9.12%
Julie JohnsonDMar 12, 2025Feb 12, 2025Sell$1,001 - $15,000+18.92%
Julie JohnsonDFeb 12, 2025Jan 15, 2025Buy$1,001 - $15,000+12.23%
Josh GottheimerDFeb 10, 2025Jan 24, 2025Sell$1,001 - $15,000+16.82%